扶正活萎汤治疗气虚络瘀型慢性萎缩性胃炎临床研究
Clinical Study of Fuzheng Huowei Decoction in the Treatment of Qi Deficiency and Collateral Stasis Type Chronic Atrophic Gastritis
-
摘要: 目的 观察扶正活萎汤治疗气虚络瘀型慢性萎缩性胃炎（CAG）的临床疗效。方法 将65例气虚络瘀型CAG患者根据SPSS软件随机列表法随机分为治疗组33例和对照组32例。治疗组予扶正活萎汤口服，每日1剂；对照组予胃复春片口服，每日3次，每次4片。治疗3个月后比较2组中医证候积分、胃镜和病理疗效以及血清胃蛋白酶原Ⅰ、Ⅱ（PGⅠ、PGⅡ）、PGⅠ/PGⅡ比值（PGR）及胃泌素（G-17）等结果差异。结果 治疗后2组中医证候积分均较治疗前降低（P<0.05~0.01），治疗组优于对照组（P<0.05~0.01）。治疗组胃镜疗效、病理学组织学疗效均优于对照组（P<0.05）。治疗组PGⅠ、PGR水平明显升高（P<0.05），优于对照组（P<0.05）。治疗组总有效率为 81.8%，高于对照组68.8%（P<0.05）。结论 扶正活萎汤能够有效缓解CAG患者的临床症状，改善病理组织学病变，促进黏膜修复，其治疗CAG的作用机制可能与调节PGⅠ、PGⅡ、PGR、G-17等水平相关。Abstract: OBJECTIVE To observe the clinical effect of Fuzheng Huowei decoction in the treatment of qi deficiency and collateral stasis type chronic atrophic gastritis (CAG). METHODS Using a random list method on SPSS， 65 patients with qi deficiency and collateral stasis type CAG were randomly divided into the treatment group with 33 cases and the control group with 32 cases. The treatment group was given Fuzheng Huowei decoction， one dose a day. The control group was given WeiFuchun Pill， three times a day， four pills each time. After three months' treatment， such indexes of the two groups were compared as traditional Chinese medicine (TCM) syndrome scores， gastroscopy， pathological effect， along with the differences of serum pepsinogen Ⅰ， Ⅱ(PGⅠ， PGⅡ)， the ratio of PGⅠ/ PGⅡ and gastrin (G-17). RESULTS After treatment， TCM syndrome scores of the two groups were lower than that before treatment (P<0.05，P<0.01) and the treatment group was better (P<0.05，P<0.01). The gastroscopy and pathological effect in the treatment group were better than that in the control group (P<0.05). The level of PGⅠ and PGR (PGⅠ/PGⅡ) in the treatment group significantly increased (P<0.05)， which was better than that in the control group (P<0.05). The total effective rate of the treatment group was 81.8%， higher than 68.8% of the control group (P<0.05). CONCLUSION Fuzheng Huowei decoction can effectively relieve the clinical symptoms of patients with CAG， improve the histopathological lesion and promote mucosal repair， of which the mechanism in treating CAG may be functioned as regulating the levels of PGⅠ， PGⅡ， PGR and G-17.
-
[1] 马学慧，朱世楷.基于数据挖掘的朱世楷“通顺疗法”治疗慢性萎缩性胃炎的用药规律总结[J].中医药导报，2019，25(23):48-52. [2] 中华医学会消化病学分会.中国慢性胃炎共识意见[J].胃肠病学，2017， 22 (11):670-687. [3] TYTGAT GN. The sydney system: Endoscopic division endoscopic appearances in gastritis/duodenitis[J]. J Gastroenterol Hepatol， 1991， 6(3): 223-234. [4] 中华中医药学会脾胃病分会.慢性胃炎中医诊疗专家共识意见[J]. 中华中医药杂志， 2017，32(7):3060-3064. [5] 中药新药临床研究指导原则（试行）[M].北京:中国医药科技出版社，2002：124-129. [6] 姜智敏，戈之铮.胃蛋白酶原在慢性萎缩性胃炎和胃癌筛查中的价值[J].胃肠病学，2009，14(12):754-756. [7] 曹勤，冉志华.血清学检查在萎缩性胃炎和胃癌筛查中的诊断价值[J].胃肠病学，2007，12(3):172-175. [8] 国家消化系统疾病临床医学研究中心. 中国早期胃癌筛查流程专家共识意见（草案）[J].胃肠病学，2018，23(2):92-97. [9] 曹勤，冉志华，萧树东.检测血清胃蛋白酶原和胃泌素-17诊断胃癌的临床价值[J].胃肠病学和肝病学杂志，2007，16(4):361-364. [10] 戴高中.朱世楷临证经验集[M].福州：福建科技出版社，2017:15. [11] 贾成文.脾胃论白话解[M].西安:三秦出版社， 2000:42. -
点击查看大图
计量
- 文章访问数: 435
- HTML全文浏览量: 11
- PDF下载量: 351
- 被引次数: 0
下载:
